ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
ArriVent BioPharma (Nasdaq: AVBP), a clinical-stage biopharmaceutical company, has announced plans for a $75 million public offering of common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional 15% of the total securities offered.
The offering will be managed by joint book-running managers Goldman Sachs & Co. LLC, Citigroup, and Guggenheim Securities. ArriVent plans to use the proceeds to support the development of firmonertinib and other pipeline programs, along with working capital and general corporate purposes.
The offering is being conducted through an automatic shelf registration statement on Form S-3ASR filed with the SEC on February 3, 2025. A preliminary prospectus supplement and accompanying base prospectus will be available on the SEC's website.
Positive
- Potential to raise up to $75 million in fresh capital
- Additional 15% option granted to underwriters could increase total proceeds
- Strong lineup of reputable underwriters including Goldman Sachs, Citigroup, and Guggenheim Securities
- Proceeds will support development of firmonertinib and pipeline programs
Negative
- Potential dilution for existing shareholders
- Offering subject to market and other conditions, indicating execution uncertainty
News Market Reaction
On the day this news was published, AVBP gained 1.01%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions,
Goldman Sachs & Co. LLC, Citigroup and Guggenheim Securities are acting as joint book-running managers for the proposed offering.
ArriVent intends to use the net proceeds from the proposed offering, together with its existing cash resources, to support its activities for firmonertinib and its other pipeline programs and for working capital and other general corporate purposes.
An automatic shelf registration statement on Form S-3ASR relating to the securities being sold in this offering was filed with the Securities and Exchange Commission (the “SEC”) on February 3, 2025 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov, copies of which may be obtained, when available, from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, or via email: prospectus-ny@ny.email.gs.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or via telephone: (800) 831-9146; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state, province, territory or other jurisdiction.
About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
Cautionary Statement Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding ArriVent’s business strategies and plans and the proposed public offering and use of proceeds therefrom, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms or other comparable terminology, which are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Management has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While they believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond management’s control. These statements involve risks and uncertainties that may cause ArriVent’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements, as discussed in greater detail in its filings with the SEC, including without limitation, risks and uncertainties related to global economic or market conditions, the satisfaction of customary closing conditions related to the public offering, volatility in the share price of its common stock, changes in its operating plans or funding requirements and the risks and uncertainties described in the section entitled “Risk Factors” in its annual report on Form 10-K for the year ended December 31, 2024 that was filed with the SEC on March 3, 2025, its quarterly report on Form 10-Q for the quarter ended March 31, 2025 that was filed with the SEC on May 12, 2025 and its subsequent periodic and current reports filed with the SEC. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, ArriVent assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact for Investors & Media
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
What is the size of ArriVent BioPharma's (AVBP) proposed public offering?
How will ArriVent (AVBP) use the proceeds from the public offering?
Who are the underwriters for ArriVent's (AVBP) public offering?
When did ArriVent (AVBP) file the shelf registration for this offering?
What types of securities is ArriVent (AVBP) offering in this public offering?
